Warning signs include inconsistent behavior across onsite and remote environments, problems on thin or mobile devices, broken signing workflows, and failures during enrollment or transaction-level authentication. If test coverage does not include a realistic mix of users, devices, and pharmacy interactions, the organization is likely to discover issues after go-live rather than before it.
What a poorly tested EPCS rollout usually looks like
When EPCS testing is too shallow, the failures are usually practical rather than theoretical: the workflow works in a controlled demo but breaks when clinicians move between workstations, networks, and devices. The clearest warning signs are inconsistent signing behavior, fragile authentication steps, and transaction flows that only succeed under ideal conditions.
That pattern matters because EPCS is a live clinical workflow, not just a login feature. If the test plan does not exercise the real signing path end to end, teams often find that enrollment, identity verification, or device-dependent steps fail only after deployment, when the operational cost of fixing them is much higher.
Where test coverage is usually too narrow
The most common gap is environmental realism. A test lab may validate one browser, one workstation image, or one network path, but EPCS is exposed to variation in pharmacy systems, clinician endpoints, and remote access conditions. Problems on thin clients, tablets, or mobile devices are especially important because they often reveal assumptions about screen size, session handling, certificate use, or local software that were never exercised before go-live.
Another gap is user-path coverage. EPCS should be tested by role and by transaction type, not only by happy-path administrative login. If signing, enrollment, token challenge, or step-up authentication is only verified in isolation, the organization may miss failures that appear when the full workflow is chained together under time pressure. NHIMG’s Healthcare Identity Security Guide is useful here because it ties EPCS to clinician access patterns, shared workstations, and the operational realities of healthcare environments.
A third gap is interaction coverage. EPCS is rarely just a single application event, it depends on how the prescribing system, identity checks, signing component, and downstream pharmacy interaction behave together. If testing does not include realistic transitions between onsite and remote use, interrupted sessions, multi-factor prompts, and resubmission after failure, the system may appear stable while still being brittle in production.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and OWASP ASVS set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | IA-2 — Identification and Authentication (Organizational Users) | EPCS testing depends on user authentication working reliably for clinicians. |
| IA-5 — Authenticator Management | Broken EPCS enrollment and signing often point to authenticator lifecycle or challenge failures. | |
| AU-2 — Event Logging | EPCS test evidence should confirm signing and authentication events are logged for troubleshooting. | |
| Recommendation — Test organizational-user authentication across real prescribing workflows and devices. Verify authenticator enrollment, renewal, and recovery paths before go-live. Confirm EPCS events are captured with enough detail to diagnose failures. | ||
| ISO/IEC 27001:2022 | A.8.9 — Configuration management | EPCS often fails when endpoint or browser configuration differs from the tested setup. |
| Recommendation — Baseline and validate the EPCS client configuration used in production. | ||
| OWASP ASVS | V6 — Authentication | EPCS transaction-level authentication failures are a core testing signal. |
| Recommendation — Exercise authentication success, failure, and recovery paths under realistic conditions. | ||
Practitioner Guidance
What to verify: Validate the complete prescribing journey, from enrollment and authentication through signature completion and downstream handoff, on the actual device classes and access paths clinicians use. If the test evidence only covers a controlled desktop scenario, treat that as incomplete rather than reassuring.
Common mistake: Teams often overvalue one successful demo transaction and underweight failure coverage. The more useful question is whether the plan included negative tests, device diversity, remote access, and recovery from interrupted or failed signing attempts.
What good looks like: A well-tested EPCS implementation produces the same outcome across realistic clinician workflows, with predictable behavior when sessions expire, credentials are re-presented, or the user switches context between systems. The goal is not perfect uniformity, but dependable behavior under ordinary clinical variation.
Practitioner takeaway: If the only evidence is that EPCS worked once in a clean test environment, assume the rollout is still unproven; confidence should come from repeatable success across devices, roles, and transaction paths that mirror real prescribing conditions.
Related resources from NHI Mgmt Group
- What are the signs that an application allowlisting implementation is not being tested well enough?
- What are the signs that an MCP implementation is not governed well enough for production use?
- Why is single-provider AI agent governance not enough for enterprise security?
- What are the signs that LLM observability is not working well enough?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 28, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
